ArticleAmerican journal of translational research2025
Promising efficacy of alisartan isoproxil combined with probiotics in elderly hypertensive patients and analysis of cardiovascular prognostic factors.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of alisartan isoproxil tablets combined with probiotics in elderly hypertensive patients and analyze factors influencing cardiovascular prognosis.
methodsA retrospective analysis was conducted on 147 hypertensive patients treated at the East New Town Branch of Yinzhou People's Hospital Community from September 2021 to September 2023. Patients were divided into two groups based on treatment regimen: the control group (n=75, treated with alisartan isoproxil tablets) and the observation group (n=72, treated with alisartan isoproxil tablets combined with probiotics). The total effective rate, blood pressure, inflammatory markers, blood lipids, and vascular endothelial function were assessed before treatment, at 3 months, and at 6 months. The incidence of major adverse cardiovascular events (MACE) was compared between the two groups 6 months after treatment. Univariate and multivariate logistic regression analyses were used to identify risk factors for MACE.
resultsThe total effective rate in the observation group was significantly higher than that in the control group (P < 0.05). Compared to the control group, the observation group showed lower levels of systolic/diastolic blood pressure, inflammatory markers, blood lipids, endothelin-1, and vascular endothelial growth factor, with a higher level of nitric oxide (all P < 0.05). The incidence of MACE was lower in the observation group than in the control group (P < 0.05). Univariate and multivariate logistic regression analyses indicated that age, BMI, SBP, and DBP were risk factors for MACE.
conclusionAlisartan isoproxil combined with probiotics effectively improves blood pressure, inflammatory markers, blood lipids, and vascular endothelial function in elderly hypertensive patients. Age, BMI, SBP, and DBP are identified as risk factors for MACE and should be addressed early with preventive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.